Nacho Aguilo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1388170/publications.pdf Version: 2024-02-01



Масно Асило

#	Article	IF	CITATIONS
1	Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. Vaccine, 2013, 31, 4867-4873.	3.8	211
2	Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial. Lancet Respiratory Medicine,the, 2015, 3, 953-962.	10.7	148
3	Pulmonary but Not Subcutaneous Delivery of BCG Vaccine Confers Protection to Tuberculosis-Susceptible Mice by an Interleukin 17–Dependent Mechanism. Journal of Infectious Diseases, 2016, 213, 831-839.	4.0	120
4	ESX-1-induced apoptosis is involved in cell-to-cell spread of <i>Mycobacterium tuberculosis</i> . Cellular Microbiology, 2013, 15, 1994-2005.	2.1	116
5	<i>Klebsiella pneumoniae</i> survives within macrophages by avoiding delivery to lysosomes. Cellular Microbiology, 2015, 17, 1537-1560.	2.1	116
6	Reactogenicity to major tuberculosis antigens absent in BCG is linked to improved protection against Mycobacterium tuberculosis. Nature Communications, 2017, 8, 16085.	12.8	109
7	The biology of cytotoxic cell granule exocytosis pathway: granzymes have evolved to induce cell death and inflammation. Microbes and Infection, 2009, 11, 452-459.	1.9	92
8	Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial. Lancet Respiratory Medicine,the, 2019, 7, 757-770.	10.7	92
9	A Specific Polymorphism in Mycobacterium tuberculosis H37Rv Causes Differential ESAT-6 Expression and Identifies WhiB6 as a Novel ESX-1 Component. Infection and Immunity, 2014, 82, 3446-3456.	2.2	74
10	MTBVAC: Attenuating the Human Pathogen of Tuberculosis (TB) Toward a Promising Vaccine against the TB Epidemic. Frontiers in Immunology, 2017, 8, 1803.	4.8	70
11	Oxidative Phosphorylation Induces De Novo Expression of the MHC Class I in Tumor Cells through the ERK5 Pathway. Journal of Immunology, 2010, 185, 3498-3503.	0.8	58
12	Elucidating Sources and Roles of Granzymes A and B during Bacterial Infection and Sepsis. Cell Reports, 2014, 8, 420-429.	6.4	58
13	New live attenuated tuberculosis vaccine MTBVAC induces trained immunity and confers protection against experimental lethal pneumonia. PLoS Pathogens, 2020, 16, e1008404.	4.7	58
14	New insights into the transposition mechanisms of IS6110 and its dynamic distribution between Mycobacterium tuberculosis Complex lineages. PLoS Genetics, 2018, 14, e1007282.	3.5	57
15	IL-17-dependent SIgA-mediated protection against nasal Bordetella pertussis infection by live attenuated BPZE1 vaccine. Mucosal Immunology, 2018, 11, 1753-1762.	6.0	55
16	MHC-I modulation due to changes in tumor cell metabolism regulates tumor sensitivity to CTL and NK cells. Oncolmmunology, 2015, 4, e985924.	4.6	48
17	MTBVAC from discovery to clinical trials in tuberculosis-endemic countries. Expert Review of Vaccines, 2017, 16, 565-576.	4.4	48
18	Deciphering the role of IS6110 in a highly transmissible Mycobacterium tuberculosis Beijing strain, GC1237. Tuberculosis, 2011, 91, 117-126.	1.9	47

NACHO AGUILO

#	Article	IF	CITATIONS
19	Protective immunity afforded by attenuated, PhoP <i>â€</i> deficient <i>Mycobacterium tuberculosis</i> is associated with sustained generation of CD4 ⁺ Tâ€cell memory. European Journal of Immunology, 2012, 42, 385-392.	2.9	46
20	MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice. Tuberculosis, 2016, 96, 71-74.	1.9	46
21	Cell death induced by cytotoxic CD8 ⁺ T cells is immunogenic and primes caspase-3–dependent spread immunity against endogenous tumor antigens. , 2020, 8, e000528.		46
22	Pulmonary Mycobacterium bovis BCG Vaccination Confers Dose-Dependent Superior Protection Compared to That of Subcutaneous Vaccination. Vaccine Journal, 2014, 21, 594-597.	3.1	43
23	ESX-1-induced apoptosis during mycobacterial infection: to be or not to be, that is the question. Frontiers in Cellular and Infection Microbiology, 2013, 3, 88.	3.9	42
24	Bim is a crucial regulator of apoptosis induced by Mycobacterium tuberculosis. Cell Death and Disease, 2014, 5, e1343-e1343.	6.3	41
25	Stronger induction of trained immunity by mucosal BCG or MTBVAC vaccination compared to standard intradermal vaccination. Cell Reports Medicine, 2021, 2, 100185.	6.5	41
26	Update on TB Vaccine Pipeline. Applied Sciences (Switzerland), 2020, 10, 2632.	2.5	38
27	Human NK cells activated by EBV ⁺ lymphoblastoid cells overcome anti-apoptotic mechanisms of drug resistance in haematological cancer cells. OncoImmunology, 2015, 4, e991613.	4.6	36
28	Protein Kinase C-Î, ls Required for NK Cell Activation and In Vivo Control of Tumor Progression. Journal of Immunology, 2009, 182, 1972-1981.	0.8	33
29	Recent developments in tuberculosis vaccines. Expert Review of Vaccines, 2013, 12, 1431-1448.	4.4	33
30	Attenuated Mycobacterium tuberculosis SO2 Vaccine Candidate Is Unable to Induce Cell Death. PLoS ONE, 2012, 7, e45213.	2.5	32
31	MTBVAC, a live TB vaccine poised to initiate efficacy trials 100Âyears after BCG. Vaccine, 2021, 39, 7277-7285.	3.8	31
32	ERK5 Knockdown Generates Mouse Leukemia Cells with Low MHC Class I Levels That Activate NK Cells and Block Tumorigenesis. Journal of Immunology, 2009, 182, 3398-3405.	0.8	28
33	Pulmonary BCG induces lung-resident macrophage activation and confers long-term protection against tuberculosis. Science Immunology, 2021, 6, eabc2934.	11.9	27
34	Pulmonary MTBVAC vaccination induces immune signatures previously correlated with prevention of tuberculosis infection. Cell Reports Medicine, 2021, 2, 100187.	6.5	26
35	The induction of Bim expression in human T-cell blasts is dependent on nonapoptotic Fas/CD95 signaling. Blood, 2007, 109, 1627-1635.	1.4	25
36	Hyper-attenuated MTBVAC erp mutant protects against tuberculosis in mice. Vaccine, 2014, 32, 5192-5197.	3.8	24

NACHO AGUILO

#	Article	IF	CITATIONS
37	Evaluation of the immunogenicity and efficacy of BCG and MTBVAC vaccines using a natural transmission model of tuberculosis. Veterinary Research, 2019, 50, 82.	3.0	22
38	Live attenuated TB vaccines representing the three modern Mycobacterium tuberculosis lineages reveal that the Euro–American genetic background confers optimal vaccine potential. EBioMedicine, 2020, 55, 102761.	6.1	22
39	Impaired anti-leukemic immune response in PKCÎ,-deficient mice. Molecular Immunology, 2008, 45, 3463-3469.	2.2	21
40	Granzyme B of cytotoxic T cells induces extramitochondrial reactive oxygen species production via caspaseâ€dependent NADPH oxidase activation. Immunology and Cell Biology, 2010, 88, 545-554.	2.3	21
41	Mouse Cytotoxic T Cell-derived Granzyme B Activates the Mitochondrial Cell Death Pathway in a Bim-dependent Fashion. Journal of Biological Chemistry, 2015, 290, 6868-6877.	3.4	21
42	Phenotypic and functional evaluation of CD3+CD4-CD8- T cells in human CD8 immunodeficiency. Haematologica, 2011, 96, 1195-1203.	3.5	18
43	Autoimmune lymphoproliferative syndrome (ALPS) in a patient with a new germline Fas gene mutation. Immunobiology, 2007, 212, 73-83.	1.9	17
44	Cell cycle regulation by FasL and Apo2L/TRAIL in human T-cell blasts. Implications for autoimmune lymphoproliferative syndromes. Journal of Leukocyte Biology, 2008, 84, 488-498.	3.3	17
45	Evaluation of the immunogenicity and diagnostic interference caused by M. tuberculosis SO2 vaccination against tuberculosis in goats. Research in Veterinary Science, 2015, 103, 73-79.	1.9	17
46	Cytotoxicity of quinone drugs on highly proliferative human leukemia T cells: Reactive oxygen species generation and inactive shortened SOD1 isoform implications. Chemico-Biological Interactions, 2012, 198, 18-28.	4.0	16
47	Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2. Biology, 2021, 10, 208.	2.8	16
48	Antigen-specific primed cytotoxic T cells eliminate tumour cells in vivo and prevent tumour development, regardless of the presence of anti-apoptotic mutations conferring drug resistance. Cell Death and Differentiation, 2018, 25, 1536-1548.	11.2	15
49	Evaluation of the Mycobacterium tuberculosis SO2 vaccine using a natural tuberculosis infection model in goats. Veterinary Journal, 2017, 223, 60-67.	1.7	14
50	MTBVAC-Based TB-HIV Vaccine Is Safe, Elicits HIV-T Cell Responses, and Protects against Mycobacterium tuberculosis in Mice. Molecular Therapy - Methods and Clinical Development, 2019, 13, 253-264.	4.1	14
51	A human dendritic cell-based in vitro model to assess Mycobacterium tuberculosis SO2 vaccine immunogenicity. ALTEX: Alternatives To Animal Experimentation, 2014, 31, 397-406.	1.5	12
52	Respiratory Immunization With a Whole Cell Inactivated Vaccine Induces Functional Mucosal Immunoglobulins Against Tuberculosis in Mice and Non-human Primates. Frontiers in Microbiology, 2020, 11, 1339.	3.5	11
53	IFNα signaling through PKC-Î, is essential for antitumor NK cell function. Oncolmmunology, 2014, 3, e948705.	4.6	10
54	Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice. Journal of Visualized Experiments, 2016, , .	0.3	10

NACHO AGUILO

#	Article	IF	CITATIONS
55	BCC vaccination improves DTaP immune responses in mice and is associated with lower pertussis incidence in ecological epidemiological studies. EBioMedicine, 2021, 65, 103254.	6.1	10
56	Granzyme A ls Expressed in Mouse Lungs during Mycobacterium tuberculosis Infection but Does Not Contribute to Protection In Vivo. PLoS ONE, 2016, 11, e0153028.	2.5	10
57	The Mycobacterium tuberculosis PhoPR virulence system regulates expression of the universal second messenger c-di-AMP and impacts vaccine safety and efficacy. Molecular Therapy - Nucleic Acids, 2022, 27, 1235-1248.	5.1	10
58	Therapeutic efficacy of the live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in a preclinical model of bladder cancer. Translational Research, 2018, 197, 32-42.	5.0	9
59	Therapeutic efficacy of pulmonary live tuberculosis vaccines against established asthma by subverting local immune environment. EBioMedicine, 2021, 64, 103186.	6.1	8
60	<i>Mycobacterium tuberculosis</i> infection prevents asthma and abrogates eosinophilopoiesis in an experimental model. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2512-2514.	5.7	6
61	Breaking Transmission with Vaccines: The Case of Tuberculosis. Microbiology Spectrum, 2017, 5, .	3.0	6
62	Vacunación frente a tuberculosis. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2018, 36, 648-656.	0.5	4
63	Independent genomic polymorphisms in the PknH serine threonine kinase locus during evolution of the Mycobacterium tuberculosis Complex affect virulence and host preference. PLoS Pathogens, 2020, 16, e1009061.	4.7	4
64	Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors. , 2022, 10, e004325.		4
65	Vaccination against tuberculosis. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2018, 36, 648-656.	0.3	3
66	Breaking Transmission with Vaccines: The Case of Tuberculosis. , 2019, , 249-261.		0
67	Title is missing!. , 2020, 16, e1009061.		0
68	Title is missing!. , 2020, 16, e1009061.		0
69	Title is missing!. , 2020, 16, e1009061.		0
70	Title is missing!. , 2020, 16, e1009061.		0